CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 515790-516166 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T90344","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T51262","span":{"begin":169,"end":376},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}

{"project":"Epistemic_Statements","denotations":[{"id":"T1139","span":{"begin":0,"end":376},"obj":"Epistemic_statement"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T133","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T134","span":{"begin":169,"end":376},"obj":"Sentence"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1137","span":{"begin":334,"end":337},"obj":"Phenotype"}],"attributes":[{"id":"A1137","pred":"hp_id","subj":"T1137","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T2223","span":{"begin":165,"end":167},"obj":"Body_part"}],"attributes":[{"id":"A2223","pred":"uberon_id","subj":"T2223","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3294","span":{"begin":165,"end":167},"obj":"Disease"},{"id":"T3295","span":{"begin":291,"end":332},"obj":"Disease"},{"id":"T3296","span":{"begin":315,"end":332},"obj":"Disease"},{"id":"T3297","span":{"begin":334,"end":337},"obj":"Disease"},{"id":"T43485","span":{"begin":165,"end":167},"obj":"Disease"},{"id":"T90468","span":{"begin":291,"end":332},"obj":"Disease"},{"id":"T58197","span":{"begin":315,"end":332},"obj":"Disease"},{"id":"T95006","span":{"begin":334,"end":337},"obj":"Disease"}],"attributes":[{"id":"A3294","pred":"mondo_id","subj":"T3294","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A3295","pred":"mondo_id","subj":"T3295","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A3296","pred":"mondo_id","subj":"T3296","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A3297","pred":"mondo_id","subj":"T3297","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A3298","pred":"mondo_id","subj":"T3297","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A3299","pred":"mondo_id","subj":"T3297","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A59026","pred":"mondo_id","subj":"T43485","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A55436","pred":"mondo_id","subj":"T90468","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A20082","pred":"mondo_id","subj":"T58197","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A8391","pred":"mondo_id","subj":"T95006","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A77581","pred":"mondo_id","subj":"T95006","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A65898","pred":"mondo_id","subj":"T95006","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"}],"text":"Our work aims to enhance the bioavailability and effectiveness of immunomodulatory peptides that modulate CD4+ T cells and have potential therapeutic application in MS. We have used a well established altered peptide ligand (APL) model that has been shown to be therapeutically effective in experimental autoimmune encephalomyelitis (EAE) to test the efficacy of our approach."}